Seeking Alpha·6d ago
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptNurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Nurix Therapeutics is a clinical-stage biotech focused on targeted protein degradation, but its financial profile is dominated by episodic partnership revenue and heavy R&D spending. Revenue fell 79.5% year-over-year to $9.0M in 2026Q2, while R&D costs remaine...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 9, 2026 | -$0.81-12.1% vs -$0.72 | $9M-40.9% vs $15M |
Q2 2026 Apr 8, 2026 | -$0.79-3.9% vs -$0.76 | $6M-56.1% vs $14M |
Q1 2026 Jan 28, 2026 | -$0.82+2.4% vs -$0.84 | $14M+1.3% vs $13M |
Q4 2025 Oct 9, 2025 | -$1.03-22.6% vs -$0.84 | $8M-35.6% vs $12M |
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Benchmark NRIX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nurix Therapeutics, Inc. (NRIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.88 | $2.07B | -7.83 | 53.95% | -314.9% | -49.63% | — | |
| $7.83 | $505.2M | -6.12 | -0.3% | 2.94% | 1.91% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Nurix Therapeutics, Inc. (NRIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nurix Therapeutics, Inc. (NRIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 9, 2026·SEC
Jun 11, 2026·SEC
Jun 8, 2026·SEC
Get notified when NRIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nurix Therapeutics, Inc. (NRIX) stock FAQ — growth, dividends, profitability & financials explained
Nurix Therapeutics, Inc. (NRIX) reported $36.8M in revenue for fiscal year 2025. This represents a 2% decrease from $37.4M in 2018.
Nurix Therapeutics, Inc. (NRIX) grew revenue by 54.0% over the past year. This is strong growth.
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $341.4M for fiscal year 2025.
Nurix Therapeutics, Inc. (NRIX) has a return on equity (ROE) of -49.6%. Negative ROE indicates the company is unprofitable.
Nurix Therapeutics, Inc. (NRIX) had negative free cash flow of $304.5M in fiscal year 2025, likely due to heavy capital investments.
